Bristol-Myers Squibb Company (BMY) will raise its quarterly dividend by 2.7 percent to $0.38 per share. This marks the eight consecutive year of dividend increases for BMY.
Bristol-Myers Squibb Company is is a global specialty biopharmaceutical company. Bristol-Myers is developing new medicines in the following core therapeutic areas: oncology with a priority in certain tumor types; immunoscience with priorities in psoriasis, lupus, RA and inflammatory bowel disease; cardiovascular with a priority in heart disease and; fibrotic disease with priorities in lung and liver. The company's top drugs include Opdivo (infused biologic immuno-oncology treatment) and Eliquis (anticoagulation).